Fluicell AB

Research Fluicell AB (FLUI) on Bullrun: market cap SEK 49.45M, P/E 0.1. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is SEK 49.45M; P/E is 0.1.

Peer valuation comparison

Latest P/E is 0.05x versus a Healthcare sector median of 24.46x (99.8% below).

Latest P/E is 0.05x versus a Sweden median of 18.57x (99.7% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025SEK 6.00M-SEK 8.33M-SEK 13.66M218.8%-6.07SEK 2.26Mn/aSEK 10.90M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-27SEK 49.45M0.1n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 SEK.

About Fluicell AB

Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Fluicell AB's market cap?

Fluicell AB's market capitalization is SEK 49.45M.

What is Fluicell AB's P/E ratio?

Fluicell AB's price-to-earnings (P/E) ratio is 0.1.

What does Fluicell AB do?

Fluicell AB (publ), a life science company, develops and provides clay instruments for 3D bioprinting and cell analysis and flow control on single-cell level in Sweden. The company offers BIOPEN, a powerful tool for high precision cell biology that uses open volume microfluidics; Biozone 6 that generate dose-response curves or study the effects of multiple drug compounds; and Dynaflow Resolve system, an ion channel screening platform, which allows to record various ion channel current in patch clamp recording configuration.